Drugs / DCC-3009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06630234 | Dec 2024 → May 2028 expected | gastrointestinal stromal tumor | Deciphera Pharmaceuticals, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-14 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 deciphera.com ↗
New Pan-KIT Development Candidate DCC-3009 for GIST Demonstrates Potential Best-in-Class Profile with Broad Coverage of KIT Mutations with High Selectivity |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-14 | Deciphera Pharmaceuticals, LLC | Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 deciphera.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCC-3009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06630234 ↗ |
| Route | Oral | “Administered orally” NCT06630234 ↗ |